Breaking News

AstraZeneca Licenses Early Stage Cardiovascular Asset for $100M Upfront

Aims to develop small molecule Lipoprotein disruptor in cardiovascular disease indications.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd. (CSPC) to advance the development of an early stage, small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits in dyslipidaemia. This asset aims to help address the major risk factors driving chronic cardiovascular disease.     CSPC will receive an upfront payment of $100 million from AstraZeneca. CSPC is also eligible to receive up to $1.92 billion for fur...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters